The Board of Trustees of the Leland Stanford Junior University
发明人:
Irving L. Weissman,Stephen Willingham,Doris Po Yi Ho,Piero D. Dalerba,Kelly Marie McKenna,Jens-Peter Volkmer
申请号：
US16411547
公开号：
US20190322751A1
申请日:
2019.05.14
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity； and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used； and the effect may be synergistic relative to a regimen in which a single agent is used.
